Pritesh Shah, Chief Commercial Officer at NovoCure Ltd (NVCR), sold 657 shares at $138.23 ($91K) on 2021-09-02, disclosed to the SEC on 2021-09-07.
Scheduled sale ($91k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $138.23 | 156 | $22K | 23.7% |
| 2 | $138.27 | 321 | $44K | 48.8% |
| 3 | $139.24 | 150 | $21K | 22.9% |
| 4 | $140.18 | 30 | $4K | 4.6% |
| Total | $138.57 avg | 657 | $91K | 100% |
| Filing → |
| NVCR | SELL | 2023-03-07 | $3.3M | — | Filing → |
| NVCR | SELL | 2023-03-06 | $141K | — | Filing → |
| NVCR | SELL | 2023-03-02 | $294K | — | Filing → |